Johnny Mahlangu to Half-Life
This is a "connection" page, showing publications Johnny Mahlangu has written about Half-Life.
Connection Strength
1,499
-
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
Score: 0,212
-
An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
Score: 0,191
-
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
Score: 0,187
-
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
Score: 0,160
-
Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358.
Score: 0,151
-
Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
Score: 0,133
-
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
Score: 0,131
-
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
Score: 0,100
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
Score: 0,046
-
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
Score: 0,038
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
Score: 0,033
-
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
Score: 0,031
-
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
Score: 0,030
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
Score: 0,030
-
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
Score: 0,028